Navigation Links
Stemline Therapeutics Appoints Kevin Buchi, Former CEO of Cephalon, to Its Board of Directors
Date:3/15/2012

NEW YORK, March 15, 2012 /PRNewswire/ -- Stemline Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel oncology therapeutics that target both cancer stem cells (CSCs) and tumor bulk, today announced that Kevin Buchi has joined its Board of Directors.

Since serving as Chief Executive Officer of Cephalon, Inc. through its $6.8 billion acquisition by Teva Pharmaceutical Industries (Nasdaq: TEVA) in October 2011, Mr. Buchi has served as Corporate Vice President, Global Branded Products for Teva. Mr. Buchi joined Cephalon in 1991 and held various positions, including Chief Operating Officer and Chief Financial Officer before becoming Cephalon's CEO in December 2010.

Ivan Bergstein, MD, Stemline's Chief Executive Officer, said, "We are honored to welcome Mr. Buchi to our Board of Directors. Kevin's vast experience and proven track record of success in this industry will be a tremendous asset to Stemline moving forward."

Mr. Buchi commented, "I am delighted to join Stemline's Board of Directors. The management team has done an outstanding job building out a clinical stage pipeline in an innovative area of oncology. I look forward to working with them as they advance these programs into late stage development and potentially into the marketplace."

About Stemline Therapeutics, Inc.

Stemline Therapeutics, Inc. is a clinical stage biopharmaceutical company developing novel oncology therapeutics that target both cancer stem cells (CSCs) as well as the tumor bulk. Among Stemline's drug candidates are SL-401 and SL-701, both of which have demonstrated single agent clinical activity in Phase I/II studies of advanced cancer patients. In a multicenter Phase I/II trial in patients with advanced acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), SL-401 demonstrated single agent activity, including durable complete responses (CRs), and an overall survival (OS) improvement relative to historical data in the most heavily pretreated AML patients. In addition, SL-401 was well-tolerated and was not toxic to the bone marrow. SL-401 is being advanced into later stage trials in advanced AML. The Company's second clinical stage therapeutic, SL-701, has demonstrated single agent activity including durable CRs and partial responses (PRs), as well as an OS benefit compared with historical data in Phase I/II trials of adult patients with refractory or recurrent glioblastoma and pediatric patients with malignant glioma. SL-701 is now poised for later stage trials in pediatric and adult patients with advanced brain cancer. Stemline is also developing a broad portfolio of preclinical small molecules and antibodies for a variety of solid and hematological cancer types. Many of these compounds have derived from the Company's proprietary discovery platform, StemScreen®. For more information, please visit the Company's website at www.stemline.com.

Stemline Contact:

Mark Jacobson
Associate Director, Business Development
Stemline Therapeutics, Inc.
750 Lexington Avenue
Sixth Floor
New York, NY 10022
Tel: 646-502-2307
Email: mjacobson@stemline.com


'/>"/>
SOURCE Stemline Therapeutics, Inc
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Stemline Therapeutics Expands Clinical Oncology Program Directed at Cancer Stem Cells With Addition of M.D. Anderson Cancer Center
2. Stemline Therapeutics, Inc. Names Eric K. Rowinsky, M.D. Chief Medical Officer and Head of Research and Development
3. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
4. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
5. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
6. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
7. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
8. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
9. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
10. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
11. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... 2017 - First major agreements signed with ... expected to grow by a CAGR of approximately 6-9% between ... company which operates globally across a number of sectors, announces that ... notable successes and is well-positioned for further expansion within the rapidly ... ...
(Date:1/17/2017)... , Jan. 17, 2017  Allergan Plc (NYSE: ... from Venus II, the second of two pivotal phase III ... in women with abnormal bleeding due to uterine fibroids.  A ... the second half of 2017. "We are pleased ... and safety profile of ulipristal acetate as shown in our ...
(Date:1/16/2017)... Research and Markets has announced the addition of the "Global ... ... drugs market to grow at a CAGR of 9.19% during the ... and the growth prospects of the global multiple myeloma drugs market ... revenue generated from the sales of branded and generic drugs used ...
Breaking Medicine Technology:
(Date:1/16/2017)... ... January 16, 2017 , ... Etymotic Research, makers ... and EB15•LE® electronic earplugs at the NSSF SHOT Show on January 17-20, 2017 ... SHOT Show is the shooting, hunting and outdoor trade show and conference for ...
(Date:1/16/2017)... ... January 16, 2017 , ... Houston dentist, Dr. Behzad Nazari, ... complimentary consultations and financing for orthodontics for a limited time. Complimentary for a ... about their orthodontic options. Walk-in, late-evening, Saturday, and same-day appointments are available. Antoine ...
(Date:1/16/2017)... (PRWEB) , ... January 16, 2017 , ... ... the availability of the newly updated International Audit Protocol Consortium (IAPC) EHS audit ... audit protocols to understand the scope of their EHS regulatory obligations and rapidly ...
(Date:1/16/2017)... ... January 16, 2017 , ... Date ... http://www.ageofautism.com/legal , Sharon Kleyne, America’s leading water educator, researcher and advocate ... syndicated radio program, The Sharon Kleyne Hour Power of Water, Global Climate Change ...
(Date:1/16/2017)... ... January 16, 2017 , ... One thing common to all ... but to test for, as well. The money spent screening for and treating cancer ... the U.S. screen patients for cancer more than in any other country that has ...
Breaking Medicine News(10 mins):